Articles related to CHEMOTHERAPY

Among patients with early-stage triple-negative breast cancer, the addition of pembrolizumab to standard chemotherapy demonstrated a 4.9 percentage point improvement in 5-year overall survival.

Experts note that the use of chemotherapy can indicate cancer spread beyond its origin, potentially reflecting the stage, aggressiveness, or progression potential of the disease.

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

In a phase 3 trial, osimertinib significantly improved median progression-free survival to 39.1 months in patients with unresectable stage III EGFR-mutated NSCLC following chemoradiotherapy, compared to 5.6 months with placebo.

A 73-year-old woman’s worsening rash and complex medical history culminated in a diagnosis of angioimmunoblastic T-cell lymphoma, underscoring the need for thorough diagnostic evaluation and aggressive treatment.

Recent trials in NSCLC treatment reveal that perioperative immunotherapy, including combinations like nivolumab and chemotherapy, can significantly improve disease-free survival in early-stage resectable NSCLC.